T-cell leukemias and lymphomas are rare blood cancers that are difficult to treat and often have poor outcomes. One promising way to improve care is personalised medicine, which aims to match treatments to the unique biological features of each patient and their cancer. This approach could help patients receive more effective therapies with fewer side effects. However, personalised medicine is not yet widely used for these cancers because research efforts are scattered, diagnostic methods differ between centres, reliable biological markers are limited, and there are too few clinical trials.

The IMPACT-T networking event aims to overcome these challenges by bringing together researchers, doctors, patient organisations, policymakers and industry partners from across Europe. Participants will share knowledge and lessons learned from previous EU-funded research projects and work together to identify gaps that are slowing progress. Importantly, patient perspectives will play a central role, ensuring that future research reflects patients’ needs and priorities.

During the event, participants will jointly develop new ideas for clinical trials that use biological markers to better match patients with treatments. The outcomes will include practical trial concepts, clear next steps for testing and funding, and stronger long-term collaborations within a European research community focused on T-cell cancers. The results will be widely shared through patient organisations, professional networks and public communication, helping to move personalised medicine closer to real-world care for people with T-cell leukemias and lymphomas.

The aim of the IMPACT-T networking event is to accelerate the translation of personalised medicine approaches into clinical trials for T-cell leukemias and lymphomas by strengthening collaboration across disciplines and sectors. The event is jointly organised by partners from the ERA / EP PerMed projects JAKSTAT-TARGET, ImmuneT-ME, and SURPASS-TNBC, building on their complementary expertise in biomarker-driven research, clinical translation and patient advocacy. Key translational stakeholders involved include clinicians, translational researchers, patient organisations, and clinical trial experts working in T-cell malignancies. In addition, major (inter)national stakeholders outside ERA / EP PerMed – such as policymakers, regulatory experts, and industry partners – will actively contribute to the discussions. The objectives are to identify translational gaps, align diagnostic and biomarker strategies, and co-create feasible, patient-centred clinical trial concepts. The networking event is planned to take place in Leipzig, Germany, in November 2026, and will serve as a foundation for sustained European collaboration and future joint initiatives.